Keywords: Takeda, Zinfandel, Actos, Alzheimer's disease biomarker

Takeda in up to $87 million deal with Zinfandel for Alzheimer’s biomarker in combination with Actos

Article | 12 January 2011

Japan’s largest drugmaker Takeda Pharmaceutical (TSE: 4502 ) has entered into an exclusive, worldwide licensing accord with privately-held USA-based Zinfandel ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in